News & Events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis

5 November 2020

American Journal of Medicinal Chemistry distinguishes OncoArendi publication on OATD-01

21 October 2020

OncoArendi Therapeutics expands the therapeutic potential of its Chitinase Platform

13 October 2020

OncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients

11 September 2020

OncoArendi Therapeutics has received the final report from the phase Ib clinical trial of innovative drug candidate OATD-01

10 September 2020

Dr. Zbigniew Zasłona joins OncoArendi Therapeutics as the new Director of the Biology Department. Dr Paweł Dobrzański, the current head of the Biology Department, will still be engaged in collaboration with OncoArendi as Senior Scientific Advisor on the company’s Scientific Advisory Board.

9 September 2020

Events & Presentations

R&D Day Presentation, 07.12.2022

7 December 2022

Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches – February 19-23, 2020 | Victoria, BC, Canada

27 February 2020

EFMC-ASMC’19 – September 1-5, 2019 | Athens, Greece

11 September 2019

ACS National Meeting & Expo – August 25 – 29, 2019 | San Diego, CA

4 September 2019

ATS- International Conference – Dallas, 17-22.05.2019

22 May 2019

EFMC – YMCS – Young Medicinal Chemist Symposium – Ljubljana 02-06.09.2018

17 September 2018
This site is registered on as a development site.